海尔生物: 海尔生物2025年半年度募集资金存放与使用情况专项报告

Fundraising Overview - The company raised a total of RMB 1,156,905,698.60 after deducting issuance costs of RMB 4,670,375.54, with the net amount available for use being RMB 1,156,905,698.60 [1][4] - As of June 30, 2025, the company had utilized RMB 1,029,056,832.19 for fundraising projects, with a remaining balance of RMB 52,258.70 [1][4] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure proper use and management of the funds [1][2] - A tripartite agreement for the special account storage of fundraising was signed with Guotai Junan Securities and Bank of China, ensuring dedicated management of the funds [2][3] Fund Usage - The company has not used any idle funds for working capital during the reporting period, and all funds have been allocated according to the approved projects [4][6] - The company approved the use of RMB 15,000,000 of temporarily idle funds for cash management, with a maximum of RMB 4,700,000 allocated for permanent working capital [5][8] Compliance and Reporting - The company has adhered to all legal and regulatory requirements regarding the use of fundraising, with no violations reported [6][7] - The board of directors and supervisory board confirmed that the information disclosed regarding the fundraising usage is timely, accurate, and complete [7][9]